Authors :
Renyiska Yula; Prof. apt. Fatma Sri Wahyuni; Dr. apt. Hansen Nasif, Sp. FRS
Volume/Issue :
Volume 6 - 2021, Issue 7 - July
Google Scholar :
http://bitly.ws/9nMw
Scribd :
https://bit.ly/3sd2BcI
Abstract :
Thalassemia major, as a red blood cell disorder
that is passed from both parents to their children,
requires high costs and the use of iron chelation drugs
throughout the patient's life. Pharmacoeconomics studies
in patients with thalassemia major needs to be conducted
to determine the efficiency and effectiveness of selecting
oral iron chelation drugs. This study aims to analyze the
cost and cost-effectiveness of using oral iron chelation
drugs such as deferasirox and deferiprone in patients with
thalassemia major at RSUP Dr. M. Djamil Padang in
2018-2019. Data was collected retrospectively using total
sampling from patient medical records and hospital
information system data. Cost parameters include
accommodation costs, medical treatment costs, laboratory
costs, and drug costs. The effectiveness parameter used is
a decrease in serum ferritin levels. Based on the results of
this study, the average total cost per treatment for
thalassemia major patients who used deferasirox (IDR
401,940,001,-) was more expensive than deferiprone (IDR
269,261,557,-). The effectiveness of deferasirox (1309
ng/mL) was bigger than that of deferiprone (830 ng/mL).
The cost-effectiveness ratio of deferasirox (IDR 307,059,-/)
was lower than deferiprone (IDR 324,412,-/). To change
the drug from deferiprone to deferasirox requires an
additional cost of IDR 276,990 per one additional unit.
From the average cost-effectiveness ratio, it can be
concluded that deferasirox is more cost-effective than
deferiprone.
Keywords :
Thalassemia Major; Oral Iron Chelation; Cost Effectiveness Analysis; Pharmacoeconomics; Deferasirox; Deferiprone
Thalassemia major, as a red blood cell disorder
that is passed from both parents to their children,
requires high costs and the use of iron chelation drugs
throughout the patient's life. Pharmacoeconomics studies
in patients with thalassemia major needs to be conducted
to determine the efficiency and effectiveness of selecting
oral iron chelation drugs. This study aims to analyze the
cost and cost-effectiveness of using oral iron chelation
drugs such as deferasirox and deferiprone in patients with
thalassemia major at RSUP Dr. M. Djamil Padang in
2018-2019. Data was collected retrospectively using total
sampling from patient medical records and hospital
information system data. Cost parameters include
accommodation costs, medical treatment costs, laboratory
costs, and drug costs. The effectiveness parameter used is
a decrease in serum ferritin levels. Based on the results of
this study, the average total cost per treatment for
thalassemia major patients who used deferasirox (IDR
401,940,001,-) was more expensive than deferiprone (IDR
269,261,557,-). The effectiveness of deferasirox (1309
ng/mL) was bigger than that of deferiprone (830 ng/mL).
The cost-effectiveness ratio of deferasirox (IDR 307,059,-/)
was lower than deferiprone (IDR 324,412,-/). To change
the drug from deferiprone to deferasirox requires an
additional cost of IDR 276,990 per one additional unit.
From the average cost-effectiveness ratio, it can be
concluded that deferasirox is more cost-effective than
deferiprone.
Keywords :
Thalassemia Major; Oral Iron Chelation; Cost Effectiveness Analysis; Pharmacoeconomics; Deferasirox; Deferiprone
